Tags : Primary Progressive Multiple Sclerosis

Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies

Shots: The P-III OPERA, ORATORIO and OBOE studies result involves assessing of Ocrevus (ocrelizumab) vs PBO in patients with RMS and PPMS, presented at AAN Annual Meeting Results: reduction in risk of disability progression associated with exposure and lower B-cell levels & permanent disability progression; @24wks. reduction in CDP; @48wks. RMS, PPMS patients with CDP […]Read More